On October 31, Jinyu Bio-Technology (600201.SH) announced that, in accordance with the National Veterinary Drug Administration Regulations and Veterinary Drug Registration Measures, after review by the Ministry of Agriculture and Rural Affairs, the fully owned subsidiary Jinyu Baoling Biopharmaceutical Co., Ltd. (referred to as 'Jinyu Baoling') participated in the research and development of the Brucellosis live vaccine (strain S19) and was approved as a new veterinary drug. The company was issued the 'New Veterinary Drug Registration Certificate'.

Brucellosis is a zoonotic infectious disease caused by Brucella. In order to effectively control bovine brucellosis, the company introduced the bovine strain Brucella S19 from the United States Department of Agriculture's Animal and Plant Health Inspection Service and the National Veterinary Bureau's laboratory. This strain has the typical smooth bovine brucella biotype 1 characteristics, weak virulence, high immunoprotection rate, genetic stability, minimal risk of inducing abortion in pregnant livestock, and enhanced conjunctival vaccination. It can reduce abortion and bacterial shedding in milk through reduced dosage and multiple administrations, allowing cows of any age to develop protective immunity without persistent antibody presence.